Kenneth Stauderman

Dr. Kenneth Stauderman


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Cell Calcium
Verified
Journal Article
Closed access
KSKenneth Stauderman
Kenneth Stauderman

1 April 2021 in Pancreas
Verified
Journal Article
Open access
CBCharles Bruen
Charles Bruen
JMJoseph B Miller
Joseph B Miller
JWJohn Wilburn
John Wilburn
CMCaleb Mackey
Caleb Mackey
TBThomas L. Bollen
Thomas L. Bollen
SHSudarshan Hebbar
Sudarshan Hebbar
Objectives: To assess the safety of Auxora in patients with acute pancreatitis (AP), systemic inflammatory response syndrome (SIRS), and hypoxemia, and identify efficacy endpoints to prospectively test in future studies. Methods: This phase 2, open-label, dose-response study randomized patients with AP, accompanying SIRS, and hypoxemia (n = 21) to receive low-dose or high-dose Auxora plus standard of care (SOC) or SOC alone. All patients received pancreatic contrast-enhanced computed tomography scans at screenings, day 5/discharge, and as clinically required 90 days postrandomization; scans were blinded and centrally read to determine AP severity using computed tomography severity index. Solid food tolerance was assessed at every meal and SIRS every 12 hours. Results: The number of patients experiencing serious adverse events was not increased with Auxora versus SOC alone. Three (36.5%) patients with moderate AP receiving low-dose Auxora improved to mild AP; no computed tomography severity index improvements were observed with SOC. By study end, patients receiving Auxora better tolerated solid foods, had less persistent SIRS, and had reduced hospitalization versus SOC. Conclusions: The favorable safety profile and patient outcomes suggest Auxora may be an appropriate early treatment for patients with AP and SIRS. Clinical development will continue in a randomized, controlled, blinded, dose-ranging study.

2 August 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MLMarilena Letizia
Marilena Letizia
YWYin‐Hu Wang
Yin‐Hu Wang
UKUlrike Kaufmann
Ulrike Kaufmann
LGLorenz Gerbeth
Lorenz Gerbeth
ASAnnegret Sand
Annegret Sand
CWCarl Weidinger
Carl Weidinger
Inflammatory bowel disease (IBD) is characterized by dysregulated intestinal immune responses. Using mass cytometry (CyTOF) to analyze the immune cell composition in the lamina propria (LP) of patients with ulcerative colitis (UC) and Crohn's disease (CD), we observed an enrichment of CD4+ effector T cells producing IL‐17A and TNF, CD8+ T cells producing IFNγ, T regulatory (Treg) cells, and innate lymphoid cells (ILC). The function of these immune cells is regulated by store‐operated Ca2+ entry (SOCE), which results from the opening of Ca2+ release‐activated Ca2+ (CRAC) channels formed by ORAI and STIM proteins. We observed that the pharmacologic inhibition of SOCE attenuated the production of proinflammatory cytokines including IL‐2, IL‐4, IL‐6, IL‐17A, TNF, and IFNγ by human colonic T cells and ILCs, reduced the production of IL‐6 by B cells and the production of IFNγ by myeloid cells, but had no effect on the viability, differentiation, and function of intestinal epithelial cells. T cell‐specific deletion of CRAC channel genes in mice showed that Orai1, Stim1, and Stim2‐deficient T cells have quantitatively distinct defects in SOCE, which correlate with gradually more pronounced impairment of cytokine production by Th1 and Th17 cells and the severity of IBD. Moreover, the pharmacologic inhibition of SOCE with a selective CRAC channel inhibitor attenuated IBD severity and colitogenic T cell function in mice. Our data indicate that SOCE inhibition may be a suitable new approach for the treatment of IBD.

27 January 2023 in Science Advances
Verified
Journal Article
Closed access
STShogo Tsujikawa
Shogo Tsujikawa
KDKaitlyn E. DeMeulenaere
Kaitlyn E. DeMeulenaere
MCMaria V. Centeno
Maria V. Centeno
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MMMegan E. Martin
Megan E. Martin
MPMurali Prakriya
Murali Prakriya
Microglia are important mediators of neuroinflammation, which underlies neuropathic pain. However, the molecular checkpoints controlling microglial reactivity are not well-understood. Here, we investigated the role of Orai1 channels for microglia-mediated neuroinflammation following nerve injury and find that deletion of Orai1 in microglia attenuates Ca 2+ signaling and the production of inflammatory cytokines by proalgesic agonists. Conditional deletion of Orai1 attenuated microglial proliferation in the dorsal horn, spinal cytokine levels, and potentiation of excitatory neurotransmission following peripheral nerve injury. These cellular effects were accompanied by mitigation of pain hyperalgesia in microglial Orai1 knockout mice. A small-molecule Orai1 inhibitor, CM4620, similarly mitigated allodynia in male mice. Unexpectedly, these protective effects were not seen in female mice, revealing sexual dimorphism in Orai1 regulation of microglial reactivity and hyperalgesia. Together, these findings indicate that Orai1 channels are key regulators of the sexually dimorphic role of microglia for the neuroinflammation that underlies neuropathic pain.

10 July 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
VSViktória Szabó
Viktória Szabó
NCNoémi Csákány-Papp
Noémi Csákány-Papp
MGMarietta Görög
Marietta Görög
TMTamara Madácsy
Tamara Madácsy
AVArpad Varga
Arpad Varga
MJMaléth József
Maléth József
Patients with recurrent acute pancreatitis (RAP) are at significant risk of developing early chronic pancreatitis (CP), which progresses into irreversible, end-stage CP with severe symptoms. There is no specific therapy in RAP or in early CP that may hinder disease progression. The pathogenesis of CP is complex and involves interactions among multiple cell types, including pancreatic acinar, ductal, and stellate cells (PSC). Therefore, it is pivotal to identify common pathogenic pathways in these cells that could be targeted pharmacologically. The Orai1-mediated store-operated Ca 2+ entry (SOCE) is a ubiquitous signaling mechanism that may become overactivated in pathological states resulting in intracellular Ca 2+ overload. In this study, we used ex vivo and in vivo preclinical disease models to demonstrate that Orai1 inhibition prevents progression of RAP and early CP. The selective Orai1 inhibitor CM5480 restored the expression of SOCE-associated regulatory factor in acinar cells, prevented uncontrolled Ca 2+ elevation, protected acinar and ductal functions, mitigated immune cell infiltration, and diminished PSC activation, proliferation, and migration. We suggest that the overactivation of Orai1 is a crucial pathogenetic event in the progression of early CP and that inhibition of Orai1 could prevent the development of end-stage CP.

7 October 2022 in Science Advances
Verified
Journal Article
Open access
YWYin-Hu Wang
Yin-Hu Wang
LNLucile Noyer
Lucile Noyer
SKSascha Kahlfuss
Sascha Kahlfuss
DRDimitrius Raphael
Dimitrius Raphael
ATAnthony Y. Tao
Anthony Y. Tao
SFStefan Feske
Stefan Feske
T cell activation and function depend on Ca 2+ signals mediated by store-operated Ca 2+ entry (SOCE) through Ca 2+ release–activated Ca 2+ (CRAC) channels formed by ORAI1 proteins. We here investigated how SOCE controls T cell function in pulmonary inflammation during a T helper 1 (T H 1) cell–mediated response to influenza A virus (IAV) infection and T H 2 cell–mediated allergic airway inflammation. T cell–specific deletion of Orai1 did not exacerbate pulmonary inflammation and viral burdens following IAV infection but protected mice from house dust mite–induced allergic airway inflammation. ORAI1 controlled the expression of genes including p53 and E2F transcription factors that regulate the cell cycle in T H 2 cells in response to allergen stimulation and the expression of transcription factors and cytokines that regulate T H 2 cell function. Systemic application of a CRAC channel blocker suppressed allergic airway inflammation without compromising immunity to IAV infection, suggesting that inhibition of SOCE is a potential treatment for allergic airway disease.